Important! Extended hours during tax season: Tuesdays, Thursdays, and Saturdays
In the pharmaceutical industry, groundbreaking science must be supported by a sophisticated financial strategy to navigate the long, high-stakes journey from discovery to market.
SMAART Company provides specialized pharmaceutical finance consulting, risk management, and strategic advisory to help your life sciences company manage immense R&D costs, complex regulatory hurdles, and intense market pressures, ensuring you can focus on the core mission of advancing patient health.
Our team of experts helps you build a resilient financial framework that optimizes the value of your intellectual property, manages the complexities of clinical trial funding, and strengthens your company for long-term growth and innovation.
Bringing a new therapy to market is one of the most capital-intensive and high-risk endeavors in any industry. Without a disciplined financial partner, even companies with promising science face significant challenges:
Massive R&D Costs & Long Development Cycles: The journey from a preclinical candidate to an FDA-approved drug can take over a decade and cost upwards of a billion dollars, requiring meticulous, long-term financial planning and capital allocation.
Complex Clinical Trial Funding & Management: Each phase of a clinical trial represents a significant financial milestone with a high risk of failure. Securing and managing the necessary capital for these trials is a constant challenge.
Stringent FDA & Global Regulatory Hurdles: Navigating the complex regulatory pathways of the FDA, EMA, and other global health authorities is a major administrative and financial burden, with significant costs tied to compliance and data submission.
Intellectual Property (IP) & Patent Management: A company’s value is intrinsically tied to its patent portfolio. Managing patent lifecycles, navigating potential litigation, and valuing this IP are critical financial functions.
Market Access & Payer Negotiations: Once a drug is approved, securing favorable reimbursement from payers and Pharmacy Benefit Managers (PBMs) is a complex process that directly determines the commercial success of the product.
SMAART Company helps you manage these high-stakes variables with a finance-first approach to life sciences innovation.
We serve the full spectrum of companies in the life sciences sector, including:
Pre-Revenue & Clinical-Stage Biotech Companies focused on managing cash burn, securing venture capital or partnership funding, and planning for future clinical trials.
Commercial-Stage Pharmaceutical Companies managing product launch costs, revenue recognition, and negotiations with the payer ecosystem.
Medical Device Companies navigating their own unique FDA approval pathways (e.g., 510(k), PMA) and managing complex supply chains for manufacturing.
Contract Research Organizations (CROs) & Contract Manufacturing Organizations (CMOs) managing project-based revenue, client contracts, and operational efficiency.
Life Science Investors & Venture Capital Firms performing due diligence on potential investments and providing financial oversight for their portfolio companies.
At SMAART Company, we understand that in life sciences, your financial strategy is inseparable from your clinical and regulatory strategy. Our dedicated focus means:
We Know Life Science Finance: We are experts in R&D capitalization, clinical trial budgeting, and the valuation of intangible assets like intellectual property and in-process research and development (IPR&D).
We Speak Your Language: We provide financial support that understands the nuances of FDA approval phases, patent cliffs, and the complex revenue cycle involving distributors, payers, and PBMs.
We Provide Forward-Looking Advisory: We specialize in creating the long-range financial models and cash-burn analyses that are critical for making strategic decisions and raising capital.
We Prepare You for the Next Stage: We help you implement audit-ready financial systems and controls that are essential for securing funding, going public (IPO), or being acquired (M&A).
We Prioritize Your Data Security: Your confidential clinical trial data, intellectual property, and strategic plans are managed with the highest level of security and discretion.
Life Science & R&D Accounting: Specialized services including proper accounting for R&D costs, capitalization of intangible assets, and equity-based compensation.
Tax Planning & R&D Tax Credits: Strategic advisory focused on maximizing the R&D tax credit, managing Net Operating Losses (NOLs), and structuring tax-efficient partnerships.
Fractional CFO & Strategic Advisory: High-level financial guidance on fundraising strategy, cash runway management, clinical trial budgeting, and partnership (licensing/buyout) deal modeling.
M&A and IPO Readiness: Comprehensive support to prepare your financial statements, systems, and controls for the rigorous due diligence process of an acquisition or public offering.
Valuation Services: Performing independent valuations of intellectual property, IPR&D, and overall enterprise value for financing, partnerships, or M&A.
Revenue Recognition & Commercialization Support: Guidance on the complex revenue recognition standards (ASC 606) for product sales, licensing agreements, and royalties.
Life science leaders should be focused on research, clinical development, and bringing life-changing therapies to patients—not on wrestling with complex valuation models or managing cash burn. With SMAART Company as your partner, you gain the financial discipline and strategic insight to navigate the path to commercialization with confidence.
Every life science company has a unique journey. Let’s build a pharmaceutical finance consulting plan that matches your specific milestones. Let’s build a support plan that matches yours. Whether you need help managing your clinical trial budget, preparing for a fundraise, or full back-office support—we’re ready to assist.
We specialize in detailed cash runway analysis and forecasting. We create a long-range budget that maps out all anticipated R&D and operational costs against your current funding, giving you a clear view of your financial runway so you can make critical decisions and plan your next fundraise.
We meticulously track and document all of your qualifying research and development expenditures throughout the year. Our expertise ensures you receive the maximum tax credit you are entitled to, which is a critical source of non-dilutive funding.
A specialist understands the unique accounting and valuation issues of the industry, from how to treat R&D costs to the complex valuation of intellectual property. This expertise is critical for accurate financial reporting, raising capital, and passing investor due diligence..
Yes. This is a core service. We help you establish “audit-ready” financials and robust internal controls, and we prepare the detailed financial models and documentation that potential acquirers will scrutinize during the due diligence process.
It begins with a detailed consultation to understand your science, your clinical development stage, and your financial objectives. From there, we design a tailored service package to support your company’s growth.
